Research News

New research presented at the annual Congress of the European Alliance of Associations for Rheumatology (EULAR) suggests that continuing urate-lowering therapy (ULT) remains the most effective strategy for maintaining remission in patients with gout, although some patients may successfully remain symptom-free after discontinuing treatment.

Prescribing antibiotics for common sore throats may have only a minimal impact on preventing serious streptococcal infections, according to new research from the University of Gothenburg. The findings challenge a widely debated rationale for antibiotic use and highlight the importance of recognizing early signs of severe illness instead.

A new review suggests that routinely prescribing antibiotics after hospital discharge may provide little benefit for children recovering from complicated acute appendicitis (CAA). The findings add to growing concerns about unnecessary antibiotic exposure and its potential role in adverse effects and antimicrobial resistance.

Researchers from The University of Osaka have developed an innovative mRNA-based treatment that could help protect the heart from long-term damage following a heart attack. In a new study, scientists found that delivering a combination of five therapeutic mRNAs directly to damaged heart tissue significantly improved heart function and survival in mice that had experienced myocardial infarction (heart attack).

OrigAMI-4 study shows strong tumor responses in patients with recurrent or metastatic head and neck cancer after standard treatments fail. Johnson & Johnson has announced promising clinical results for its investigational therapy RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) in patients with advanced head and neck squamous cell carcinoma (HNSCC), a disease where treatment options remain limited once standard therapies stop working.

Atherosclerosis, the gradual buildup of fatty deposits inside arteries, remains one of the leading causes of heart attacks and strokes worldwide. While inflammation has long been recognized as a major contributor to the disease, new research from scientists at Ludwig Maximilian University of Munich suggests that certain inflammatory immune cells may also play a protective role in slowing its progression.

Medicines commonly prescribed to treat anemia in patients with chronic kidney disease may have an unexpected role in cancer therapy, according to a new study from Finland. Researchers have found that a class of anemia drugs known as HIF-prolyl hydroxylase inhibitors (HIF-PHIs) can interfere with cancer-related processes, potentially helping patients manage both anemia and tumor progression at the same time.